Pancreatic cancer - historical

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main pancreatic cancer page for current regimens.

3 regimens on this page
3 variants on this page


Metastatic disease, first-line

PEFG

back to top

PEFG: Platinol (Cisplatin), Epirubicin, Fluorouracil, Gemcitabine

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Reni et al. 2005 2000-2003 Phase III (E-esc) Gemcitabine Seems to have superior PFS

Chemotherapy

28-day cycles

References

  1. Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. link to original article contains protocol PubMed

Metastatic disease, all lines of therapy

SMF

back to top

SMF: Streptozotocin, Mitomycin, 5-Fluorouracil

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Kelsen et al. 1991 1987-1989 Phase III (C) CAC Superior OS

Chemotherapy

References

  1. Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991 Sep 1;68(5):965-9. link to original article PubMed